Clover Partners LP Lifted Its Bancorp New Jersey New (BKJ) Stake; 2 Analysts Are Bullish Meridian Bioscience, Inc. (VIVO) Last Week

January 14, 2018 - By Vivian Park

Among 5 analysts covering Meridian Bioscience (NASDAQ:VIVO), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. Meridian Bioscience had 10 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was maintained by Canaccord Genuity with “Hold” on Thursday, September 10. Piper Jaffray maintained the shares of VIVO in report on Thursday, September 21 with “Sell” rating. The rating was maintained by Piper Jaffray on Thursday, October 19 with “Sell”. The stock of Meridian Bioscience, Inc. (NASDAQ:VIVO) has “Hold” rating given on Thursday, October 19 by Robert W. Baird. The rating was upgraded by Hilliard Lyons to “Buy” on Monday, March 28. The stock of Meridian Bioscience, Inc. (NASDAQ:VIVO) has “Neutral” rating given on Monday, March 21 by Hilliard Lyons. As per Thursday, July 27, the company rating was maintained by Piper Jaffray. See Meridian Bioscience, Inc. (NASDAQ:VIVO) latest ratings:

19/10/2017 Broker: Robert W. Baird Rating: Hold New Target: $15.0 Maintain
19/10/2017 Broker: Piper Jaffray Rating: Sell New Target: $10.0 Maintain
21/09/2017 Broker: Piper Jaffray Rating: Sell New Target: $9.0 Maintain
27/07/2017 Broker: Piper Jaffray Rating: Sell New Target: $9.0000 Maintain

Clover Partners Lp increased Bancorp New Jersey Inc New (BKJ) stake by 55.37% reported in 2017Q3 SEC filing. Clover Partners Lp acquired 153,569 shares as Bancorp New Jersey Inc New (BKJ)’s stock rose 17.75%. The Clover Partners Lp holds 430,898 shares with $7.82M value, up from 277,329 last quarter. Bancorp New Jersey Inc New now has $122.72 million valuation. The stock decreased 0.20% or $0.04 during the last trading session, reaching $17.85. About 177 shares traded. Bancorp Of New Jersey, Inc. (NYSEMKT:BKJ) has risen 44.70% since January 14, 2017 and is uptrending. It has outperformed by 28.00% the S&P500.

The stock decreased 0.97% or $0.15 during the last trading session, reaching $15.3. About 219,396 shares traded. Meridian Bioscience, Inc. (NASDAQ:VIVO) has declined 26.84% since January 14, 2017 and is downtrending. It has underperformed by 43.54% the S&P500.

Investors sentiment increased to 1.37 in 2017 Q3. Its up 0.02, from 1.35 in 2017Q2. It increased, as 12 investors sold Meridian Bioscience, Inc. shares while 42 reduced holdings. 24 funds opened positions while 50 raised stakes. 36.26 million shares or 2.14% more from 35.50 million shares in 2017Q2 were reported. Hancock Holdg holds 0.05% or 76,397 shares. Moreover, Gsa Cap Prns Limited Liability Partnership has 0.11% invested in Meridian Bioscience, Inc. (NASDAQ:VIVO) for 111,317 shares. Tower Research Cap Ltd Com (Trc) accumulated 4,325 shares. Pub Sector Pension Board accumulated 26,771 shares. Sei Invs holds 0% or 166 shares in its portfolio. Los Angeles Cap Management & Equity Research Inc stated it has 87,401 shares. 7,000 are held by First Manhattan. Hartford Invest Management, a Connecticut-based fund reported 11,600 shares. Prudential Public Limited Company reported 923,400 shares. 5.49 million are held by Brown Cap Ltd Liability Corp. Wells Fargo Company Mn owns 636,190 shares for 0% of their portfolio. Moreover, Mason Street Llc has 0% invested in Meridian Bioscience, Inc. (NASDAQ:VIVO). State Street holds 0% or 1.20 million shares in its portfolio. First Quadrant L P Ca stated it has 15,638 shares or 0% of all its holdings. Renaissance Techs Lc has invested 0.03% in Meridian Bioscience, Inc. (NASDAQ:VIVO).

Meridian Bioscience, Inc., a life science company, develops, makes, distributes, and sells diagnostic test kits primarily for various gastrointestinal, viral, respiratory, and parasitic infectious diseases worldwide. The company has market cap of $647.31 million. The firm operates through Diagnostics and Life Science divisions. It has a 30 P/E ratio. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the illumigene brand; rapid immunoassays, a single-use immunoassays that can be used in point-of-care settings under the TRU, ImmunoCard, and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the Premier brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: